Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced its participation at investor conferences during the month of March.
WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March.
3/6/24
9:10 AM ET
GI/Microbiome Panel Discussion at the TD Cowen 44th Annual Health Care Conference
10:30 AM ET
Fireside Chat at the TD Cowen 44th Annual Health Care Conference
3/13/24
Jefferies Biotech on the Bay Summit
and
Leerink Partners 2024 Global Biopharma Conference
A live webcast of the panel discussion and fireside chat at the TD Cowen 44th Annual Health Care Conference will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
